Ankylosing spondylitis
From the Journals
TNFi treatment shows hint of slowing axial spondyloarthritis radiographic progression
But no effects on slowing spine or sacroiliac joint progression were seen in eight studies of NSAIDs and in one study of secukinumab.
Conference Coverage
Repeat LTBI testing best in patients taking biologics with new risk factors
ATLANTA – Just 1.2% of patients taking biologics with negative tuberculosis test results converted to positive results in annual tuberculosis...
News from the FDA/CDC
FDA approves infliximab-axxq for numerous indications
This is the fourth biosimilar for this tumor necrosis factor inhibitor to receive FDA approval.
Commentary
Evidence grows for early axSpA treatment, uveitis flare prevention
Findings from the C-axSpAnd and C-VIEW studies of certolizumab pegol show the importance of short symptom duration in...
Conference Coverage
Certolizumab may reduce uveitis flares, axSpA disease activity
ATLANTA – Certolizumab pegol shows multiple benefits – and improved benefit with earlier treatment – for axial spondyloarthritis.
Conference Coverage
Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis
ATLANTA – The selective JAK1 inhibitor upadacitinib had a rapid effect, with a clear difference emerging between the treatment and placebo groups...
Commentary
More studies like VERVE needed to test live vaccines in special populations
“This study was narrow in nature and we certainly need more information on the safety of Zostavax with patients on biologics with other mechanisms...
Conference Coverage
Newer IL-17 inhibitors make their case in phase 3 nonradiographic axial spondyloarthritis trials
There appears to be very little to favor either ixekizumab or secukinumab over the other.
Conference Coverage
COAST-X top-line results: Ixekizumab improves nonradiographic axSpA vs. placebo
ATLANTA – Adding ixekizumab to conventional background medications significantly improved the signs and symptoms of nonradiographic axSpA in the...
News from the FDA/CDC
FDA announces approval of fifth adalimumab biosimilar, Abrilada
Pfizer said that current plans are to launch the drug in the United States in 2023.
Conference Coverage
PREVENT trial shows benefits of secukinumab for nonradiographic axSpA
ATLANTA – The trial of 555 patients “is the largest study done for a biologic agent in nonradiographic axial spondyloarthritis,” said Dr. Atul A....